This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Indaptus Therapeutics’s 8K filing here.
Indaptus Therapeutics Company Profile
Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
Featured Articles
- Five stocks we like better than Indaptus Therapeutics
- How to buy stock: A step-by-step guide for beginners
- Nebius Group: Market Overreaction or Real AI Disruption?
- Top Stocks Investing in 5G Technology
- The Best Way to Invest in Gold Is…
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Why Nike Stock Could Be 2025’s Top Comeback Play
